Clinical Trials Logo

Citation(s)

  •   Schonfeld K, Mahnke K, Schallenberg S, et al
    : Treatment of melanoma bearing individuals with ONTAKĀ® depletes regulatory T cells resulting in an augmented immune response following vaccination. [Abstract] J Invest Dermatol 126 (Suppl S3): A-594, s101, 2006.

A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA

Details for clinical trial NCT00128622